The mRNA vaccine CDMO market is rapidly expanding, driven by growing biotech startups, limited in-house manufacturing, and ...

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other ...

(Reuters) -Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major ‌step in strengthening the company's domestic production ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...

KIGALI, Rwanda, December 18, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing ...

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the onshoring of drug product manufacturing to its Moderna Technology Center in ...

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...